Target intelligence / Profile preview

Long intergenic non-protein coding RNA 1031 (LINC01031)

Target
LINC01031
Molecular classification
Long non-coding RNA (lncRNA), Long intergenic non-coding RNA (lincRNA), Other
01

Overview

Long intergenic non-protein coding RNA 1031 (LINC01031) is a long intergenic non-coding RNA (lincRNA) that does not overlap protein-coding genes and is greater than 200 nucleotides in length[1][5][7]. LINC01031 is expressed in various tissues and has been identified as a risk-associated lincRNA in lung squamous cell carcinoma, where its overexpression correlates with poor clinical prognosis and may mark malignancy[2]. While the specific mechanisms of LINC01031 function remain to be elucidated, lincRNAs such as LINC01031 are thought to regulate gene expression, chromatin remodeling, and RNA stability, and could modulate the expression of neighboring genes in a tissue-specific manner[1][5]. The precise physiological and pathological roles of LINC01031 are under investigation, but current evidence supports its relevance as a molecular marker and a potential therapeutic target in oncology[2].

Other names
TCONS_00000361LINC01031
02

Mechanism of action

Not determined for drugs, as no drugs are known to act directly on LINC01031[2]. Potential molecular functions (not drug mechanisms) include transcriptional and chromatin landscape regulation, as established for lincRNAs generally[1][5].

03

Biological functions

Transcriptional regulationChromatin remodelingPotential modulation of gene expression (inferred from general lincRNA functions)[1][5]RNA stabilization (general lincRNA function)[1][5]
04

Disease associations

Cancer (specifically associated with lung squamous cell carcinoma prognosis)[2]Other (potential roles in disease, inferred from lincRNA category)[1][5]
05

Safety considerations

No direct therapeutic interventions reported; thus, safety concerns specific to targeting LINC01031 are unknown. General challenges for lncRNA targeting include tissue specificity, off-target effects, and delivery issues[1][5]
06

Interacting drugs

None specifically reported. No evidence for direct pharmacological agents binding or modulating LINC01031 was identified in the current literature[2]
07

Biomarkers

Overexpression of LINC01031 is correlated with poor prognosis in primary lung squamous cell carcinoma (LSqCC), suggesting its value as a prognostic biomarker[2]

Beyond the preview

Go deeper on Long intergenic non-protein coding RNA 1031 (LINC01031).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Long intergenic non-protein coding RNA 1031 (LINC01031).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call